Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) - Global Forecast, 2023 - 2032

Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) - Global Forecast, 2023 - 2032

Antibody therapy market size is projected to expand at 11.8% CAGR from 2023 to 2032. The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is fueling the demand for several targeted and personalized treatments.

The increasing advancements in biotechnology and immunology are encouraging the development of novel and more effective antibody therapies. For instance, in September 2023, Manaolana Oncology Inc. was officially launched through a collaboration between The University of Texas MD Anderson Cancer Center and Panacea Venture to develop and advance in antibody-based therapies for targeting the emerging cancer antigens. Additionally, the growing awareness of the benefits of antibody therapy, including reduced side effects and improved treatment outcomes will escalate their demand. The rising investments in R&D activities for antibody-based drugs and the expanding application scope in various medical fields will further drive the market expansion.

The antibody therapy industry is segregated into type, end-use, and region.

The market share from the antibody-drug conjugates segment is estimated to rise at 11.6% CAGR from 2023 to 2032. This is mainly on account of the increasing research and development activities, the rising prevalence of cancer, and the surging advancements in biotechnology. High demand for targeted and personalized therapies will also drive the segment growth.

Antibody therapy market share from the specialty centers end-use segment is projected to rise at 12.5% CAGR between 2023 and 2032. The growth can be attributed to the growing prevalence of chronic diseases, expanding patient pool seeking specialized care, and the rising advancements in precision medicine. Moreover, specialty centers play a crucial role in delivering targeted treatments, driving the adoption of antibody therapies in these centers.

Regionally, the Europe antibody therapy market size is projected to expand at 11.6% growth rate from 2023 and 2032, due to the increasing prevalence of chronic diseases and the rising biopharmaceutical R&D investments. Furthermore, the growing awareness about personalized medicine, and the presence of favorable regulatory environment will fuel the demand for antibody therapies across the region.